Pfizer Inc. (PFE) Stock Analysis
Score BValue · Grade D · Bullish
$25.66
$25.20
-1.8%
4/10
D
Value
Investment Thesis
Price is above modeled value range. Quality supports holding but not attractive for new positions.
Trading near modeled fair value. No strong quantitative signal.
For New Investors
Price above modeled value range
For Current Holders
Quantitative score: neutral
Buy if
- Price drops 15-20% (improves asymmetry)
- Bull scenario catalysts materialize
- Market-wide correction creates opportunity
Sell if
- Bear scenario triggers occur
- Quality metrics deteriorate (ROIC declining)
- Better alternatives emerge
Valuation
Fair Value estimate: $25.20 (-1.8%). Approximately at fair value.
PEG-Based EPS
$33.36
FCF DCF Model
$33.36
EV/EBITDA
$11.59
Blended Fair Value
$25.20
Confidence
Medium
Methods
PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA
Quality Analysis
59/120 points
Low Quality
ROE (3Y Avg)
6.8%
ROIC-WACC Spread
2.4%
D/E Ratio
0.8x
Current Ratio
1.2x
Interest Coverage
6x
FCF Positive Years
3/3
Quality Flags
- Low ROE: 6.8% (need >15%, got 4/20 pts)
- ROIC spread: 2.4pp (got 6/25 pts)
- Leverage: D/E 0.8x (9/15 pts)
- Volatile gross margins: std dev 7.5pp (need <5.0pp)
Market Sentiment
Wall Street Consensus
$27.00
+5.2% Upside
27 analysts
Range: $25.00 — $35.00
Rating: Buy
Our model is slightly more cautious than Wall Street.
Trend & Technical
Price ($25.66) is 2.7% above SMA 200 ($24.99). Bullish trend confirmed.
Tech Score 61/100 — Neutral technical picture. Mixed signals across indicators.
Risk & Reward
Asymmetry Ratio
2.09:1
Expected Return
+6.9%
Bull Upside
+33.7%
Bear Downside
-16.1%
Good asymmetry: 2.09:1 ratio. Upside justifies risk.
Verdict: Favorable
Scenario Analysis
Bear
Base
Bull
Buy Zone & Action Plan
See exact entry zones, stop-loss levels, and a personalized action plan.
AI Executive Summary
Get a detailed AI-written breakdown of the investment thesis, risks, and catalysts.
Technical Analysis
RSI, MACD, moving averages, trend signals, and momentum indicators.
Ask AI about this stock
Chat with our AI analyst to ask questions about valuation, risks, or comparisons.
Frequently Asked Questions
What is the fair value of PFE?
Based on our multi-method conviction analysis, the estimated fair value of Pfizer Inc. (PFE) is $25.20. This is calculated by blending PEG-Based EPS, FCF 2-Stage DCF, EV/EBITDA and applying a quality premium of 0% based on the company's fundamentals. The confidence level of this estimate is medium.
Is PFE a buy, sell, or hold?
PFE currently has a HOLD rating with a conviction score of 4/10. Price is above modeled value range. Quality supports holding but not attractive for new positions. Price above modeled value range.
Is PFE a high-quality stock?
Pfizer Inc. has a quality grade of D (59/120 points), rated as Low Quality. Key metrics include ROE of 6.8%, ROIC-WACC spread of 2.4%, and D/E ratio of 0.8x.
What type of stock is PFE?
PFE is classified as a "value" in our framework. High dividend: 6.7%, Mature growth: -14.9%, High revenue volatility: 27.2% std dev, Large cap: $146.2B, Consistent FCF: 3/3 years positive
What do Wall Street analysts say about PFE?
27 Wall Street analysts have a consensus price target of $27.00 for PFE, representing +5.2% upside. Targets range from $25.00 to $35.00. The consensus recommendation is "Buy". Our model is slightly more cautious than Wall Street.
What are the risks of investing in PFE?
The risk/reward asymmetry ratio for PFE is 2.09:1, rated as Favorable. Good asymmetry: 2.09:1 ratio. Upside justifies risk. The expected return is +6.9%, with bull case upside of +33.7% and bear case downside of -16.1%.
What is the current trend for PFE?
PFE is in a bullish trend. Price ($25.66) is 2.7% above SMA 200 ($24.99). Bullish trend confirmed. The technical score is 61/100.
Related Stock Analyses
Best Stocks to Buy
Compare Stocks
Get the complete analysis
Scenario targets, buy zones, action plan, executive summary, technical analysis, and AI chat. All free.
Last updated: May 19, 2026 · Framework version 3.7
This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making investment decisions.